4Life Research
A 28-year-old Utah supplement company with no FTC file of any kind, publishing an unusually candid income disclosure - that covers the United States only, while its own executives describe Latin America and the US-Hispanic market as the core of the business.
The company publishes medians and time-to-rank, which almost nobody does - and the median affiliate at the rank where 65.1% sit earns $15 a month against roughly $1,200–$1,440 a year of qualification spend, in the one market it discloses.
Can you actually make money with 4Life?
Yes, under conditions, and the company deserves credit for making the conditions checkable. It publishes medians alongside averages at every one of fifteen ranks, plus the median number of months taken to reach each one, which almost nobody in this category does. No FTC action, consent order or warning letter could be located at any date, and it has traded continuously since September 1998 under the same controlling family.
The number that decides it sits in that same disclosure. Some 65.1% of the 23,185 disclosed US affiliates are at Associate, where the average is $42 a month and the median is $15 - $180 for the year. Staying commission-eligible takes 100 LP of personal volume every month, which at the company's own catalog ratio of 340 LP for $399.95 runs roughly $1,200 to $1,440 a year, before tools, events or travel the disclosure says it has not deducted.
Read the scope of that document before you rely on it. It covers the United States only, counting affiliates who received a commission payment during 2025, while the company sells in twenty-five markets and its own executives describe Latin America and the US-Hispanic market as the core of the business. The 2016 disclosure was worldwide and said approximately 80% of all distributors received no income that year. Nothing at all is published now for the majority of the field.
The published time-to-rank is the other thing worth sitting with. The median holder of the top rank took 220 months to get there - more than eighteen years. Gold Elite, 124 months. Bronze Elite, 97. Diamond Elite, 38. The company put those numbers out itself, which is to its credit, and they describe a pace that no recruiting presentation is built around.
Preferred Customer membership fee, waived on a 150 LP or larger opening order - the real cost is the 100 LP a month required to stay commission-eligible, roughly $1,200–$1,440 a year
- You can sell roughly $5,000 to $5,800 of customer orders a year. That is what covers the qualification spend at the published 25% MyShop commission on monthly customer volume above 100 LP, and it is a customer business rather than a team one.
- You are outside the United States and accept that nothing is published about you. The single disclosure counts 23,185 US affiliates in a company operating twenty-five markets, so a prospect elsewhere is evaluating an offer with no numbers attached to it.
- You can defend the price to a buyer who checks. The flagship is $82.00 for 30 servings, $2.73 a day, against mainstream bovine colostrum at roughly $0.28 a capsule, and the US patent protection has expired.
- You understand what leaving costs. On cancellation a former distributor has no right, title, claim or interest in the downline organization, and a twelve-month non-solicitation covenant follows you out of the door.
That call is computed, not chosen - the rule reads three of the nine published dimension scores and is printed on the methodology page. It describes this company's plan and the figures it publishes about the people already in it. It is not a prediction about you, and nothing on this site is advice.
Legal status
LEGAL - no court or regulator has found 4Life Research to be a pyramid scheme, and no FTC enforcement action, consent order or warning letter against the company could be located at any date, including through both 2020 rounds of FTC warning letters to multi-level marketers over coronavirus health and earnings claims. The file that does exist: an FDA warning letter addressed to founder David Lisonbee dated 1 November 2004, naming three products; a California Proposition 65 private-enforcer action over lead in herbal supplements, resolved by consent judgment on 8 June 2012 for $75,000 with no admission of liability; and a Direct Selling Self-Regulatory Council inquiry into nine social-media earnings posts, closed administratively on 22 December 2025 after the company removed posts and suspended accounts. A warning letter is not a finding of liability, a Prop 65 consent judgment is a settlement with a private enforcer rather than a state prosecution, and a self-regulatory closure is not a government action at all. One federal case, Hazel v. 4Life Research LLC (D. Utah, 2:24-cv-00487), is on the docket with its cause of action and disposition behind a paywall - the single largest open item in this file.
Confidence: Medium-High
Primary sources fetched directly where possible. Everything we could not verify is listed at the bottom of this page by name.
Follow the money
A Utah supplement company, trading since September 1998, selling immune-support products built around "transfer factor" - low-molecular-weight peptides extracted from bovine colostrum and chicken egg yolk - through a direct-selling affiliate network on a unilevel plan with generation overrides called the Life Rewards Plan.
Start with what is genuinely good, because there is more of it here than the category average. There is no FTC enforcement action, consent order or warning letter against this company at any date - including through both 2020 rounds of FTC warning letters to multi-level marketers over coronavirus claims, which caught a long list of this company’s peers and did not catch this one. That is a clean federal record for a 28-year-old immune-claims business through a pandemic, and it should be stated affirmatively rather than buried. The company has traded continuously for 28 years with no insolvency, no receivership, no relaunch and no change of controlling family, through two documented and orderly CEO handovers. And it publishes an income disclosure that gives medians alongside averages and, unusually, median months to reach each rank. Publishing that the median holder of your top rank took 220 months to get there is not a comfortable disclosure to make. Most of this sector publishes averages only, or nothing at all.
Then the numbers in that disclosure. Some 65.1% of the 23,185 disclosed US affiliates sit at Associate, where the average is $42 a month and the median is $15 - $180 for the year. Staying commission-eligible requires 100 LP of personal volume every month, and on the company’s own catalog ratio of 340 LP for $399.95, that is roughly $100–$120 a month, or $1,200–$1,440 a year. Two-thirds of the disclosed field are therefore paying substantially more to qualify than they receive in commission, before the sales tools, events and travel the disclosure itself names as costs it has not deducted. The disclaimer is honest to the point of bluntness: the company makes no guarantee of financial success, and you may lose money.
And then the gap that shapes the whole report. The disclosure is United States only. The company operates in twenty-five markets. Its own vice-president of business intelligence told a Latin America symposium in January 2025 that the business is thriving among first- and second-generation Latinos on both US coasts and in markets from Mexico to South America; the trade press profile records Spanish as the company’s first operational language and names top affiliates from Puerto Rico, Mexico, Colombia and South America; the 2026 event circuit ran Miami, Los Angeles, San Juan, Santo Domingo. No income disclosure exists for Colombia, Mexico, Peru, Ecuador, the Dominican Republic or Puerto Rico as a separate market. No country-level revenue split is published anywhere, so the size of the undisclosed field cannot be established in either direction - but a prospect being recruited in Bogotá or Santo Domingo is joining a business for which no earnings data of any kind has been published for their market. The 2016 disclosure was worldwide and said plainly that approximately 80% of all distributors received no income at all. The scope has narrowed since.
Where US affiliates sat in the 2025 disclosure
4Life’s own published income disclosure, covering 23,185 US affiliates who received a commission payment between 1 January and 31 December 2025. United States only. Commissions are gross; the disclosure states expenses are not considered.
| Product | Price | Pays |
|---|---|---|
| Preferred Customer membership Waived on an opening purchase of 150 LP or more. Since the October 2018 restructure everybody joins at this level; to earn you must additionally file a Distributor Application and enrol at least one Preferred Customer or distributor at 100 PV. |
$25 one-time |
— |
| 100 LP monthly qualification The real price of participation. Roughly $1,200–$1,440 a year at the catalog’s own 340 LP = $399.95 ratio. Can be met by MyShop customer orders rather than personal purchases - which is the honest escape hatch and the whole participant question. Six consecutive months without it cancels the agreement automatically. |
~$100–$120/mo recurring |
— |
| Transfer Factor Plus Tri-Factor Formula The flagship. A two-capsule serving gives 30 servings, so $2.73 a day. This is the product carrying the "clinically proven to activate the immune system within two hours" claim. |
$82.00 (60 capsules) per unit |
25% checkout discount / MyShop |
| Transfer Factor Tri-Factor Formula The base formula at $1.63 a day on a two-capsule serving. Roughly six times a mainstream bovine colostrum capsule. |
$49.00 (60 capsules) per unit |
25% checkout discount / MyShop |
| Loyalty Packs (340 LP) Transfer Factor, Targeted Transfer Factor and Transform packs. This is the pricing that fixes the LP-to-dollar ratio at roughly 1 LP to $1.18, which is how the monthly qualification converts into a real annual figure. |
$399.95–$414.95 per order |
— |
| Distributor Kit A kit purchase is required to become a distributor under the policies, but no price is stated in the accessible policy text and the current US figure could not be confirmed. Ask before you sign, and get the number in writing. |
not published one-time |
— |
| Annual renewal The policies describe a "material and subscription fee as determined by the Company" on or before the anniversary date, deducted automatically from bonus checks. No amount is fixed in the document and no current figure is published. An open-ended recurring fee set unilaterally by the counterparty is a term worth naming. |
open-ended annual |
— |
| Regional events and annual convention The 2026 regional circuit ran Miami, Los Angeles, San Juan and Santo Domingo with New Jersey, Chicago and Texas to follow, drawing 1,500-plus attendees across the circuit. Ticket prices and expected travel spend are not published; the income disclosure names travel and sales tools among the costs it has not deducted. |
not published per event |
— |
Who runs it, and what they ran before
BYU bachelor’s degree and MBA. On his own biographical site he records purchasing Nature’s Labs in 1985 with partners, which two years later became The Enrich Corporation, where he was co-founder, senior vice-president and president. That prior venture was a real operating Utah nutritional direct seller for over a decade - not a shell and not a collapse - and no enforcement action or failure-to-pay event is associated with it on the record reviewed. Its corporate fate after 2000 could not be confirmed to a primary source. The one adverse item against him personally is the FDA warning letter of 1 November 2004, addressed to him at the Sandy, Utah address and naming three products. Stage: warning letter. No prosecution, no consent order, no finding of liability, and no subsequent FDA warning letter to the company was located.
Co-founded the business in 1998 and established the company’s charitable foundation in 2006. She died in 2023; her daughter Jenna now leads the foundation. Noted here because the succession question in a family-controlled private company is a governance fact, and because the second generation is now inside the structure rather than outside it.
Joined in 2008 as Chief Operating Officer, became Chief Marketing Officer in 2015 and was appointed President and CEO in October 2017. Before that he was Senior Vice President of Merchandising at Overstock, and earlier its VP Finance and Controller. Accounting and finance degree, magna cum laude, University of Utah. A nine-year internal progression into the top job, from a finance and merchandising background rather than a field-leader background, is the opposite of the pattern this category usually shows.
Steve Tew was President from 2004, CEO from 2014, and moved to Vice Chairman of the Board in 2017. The founder moved to Chairman in 2014 rather than out. Danny Lee took the CEO role in October 2017 and holds it today. Two planned handovers over two decades, a founder who stepped up rather than away, no forced exits on the record, no offshore restructuring and no private-equity flip. Set against a category median where the operator is under a decade old and the founder is on their third brand, this is genuinely the strongest element of the file and it is credited as such in the ownership score.
Registered address
Sandy, Utah, USA
Privately held and family-controlled, with a corporate group spanning 4Life Research USA, LLC, 4Life Trademarks, LLC, 4Life Patents LLC, 4Life Research Europe LLC, a Spanish entity and 4Life Research Colombia LLC. There are no public filings and no audited statements, so every revenue figure here is either trade-press estimate or company statement: roughly $150 million in 2009 and $200 million in 2010 on the direct-selling trade ranking, and an estimated $300 million in 2024 and 2025. The company states $3 billion in cumulative commissions paid in its own 2026 plan document; that is unaudited. Trade association records put the footprint at twenty-five countries. The Colombian subsidiary employed 59 people in 2026 with 2025 net sales up 10.93% and net profit up 30.55% year on year, but the absolute peso figures are paywalled, so no country-level revenue split for this business exists anywhere in the public domain.
The veteran's checklist
Eight questions that decide whether this is a business or a transfer mechanism. Same eight, every review.
| Question | Answer |
|---|---|
| Who legally owns it? |
WATCH
4Life Research, LLC and 4Life Research USA, LLC - Utah limited liability companies in Sandy, Utah, privately held and controlled by the founding Lisonbee family. No public filings, no audited accounts; revenue of roughly $300 million is a trade-press estimate.
|
| What does it really cost? |
CONCERN
$25 to join as a Preferred Customer, waived on a 150 LP opening order. The real cost is 100 LP of personal volume every month to stay commission-eligible - roughly $100–$120 a month, $1,200–$1,440 a year - plus an unpublished Distributor Kit price and an open-ended annual renewal.
|
| Published income disclosure? |
CONCERN
Yes, with medians alongside averages at all fifteen ranks and median months to reach each one. It shows 65.1% of 23,185 US affiliates at Associate on a median $15 a month, and a median 220 months to reach the top rank. It covers the United States only.
|
| Does the disclosure cover the whole field? |
RED
No, and this is the central finding. It is US-only, for a company operating in twenty-five markets whose own executives describe Latin America and the US-Hispanic market as the core of the business. No earnings data of any kind is published for Colombia, Mexico, Peru, Ecuador, the Dominican Republic or Puerto Rico.
|
| Regulatory action against the company, ever? |
WATCH
No FTC action, consent order or warning letter at any date, including through both 2020 FTC rounds on coronavirus claims. The file contains an FDA warning letter to the founder dated 1 November 2004 and a California Proposition 65 lead consent judgment of $75,000 in June 2012 with no admission of liability.
|
| Is the "clinically proven" immune claim substantiated? |
CONCERN
The best-identified peer-reviewed support is a double-blind, placebo-controlled feasibility trial in four healthy participants, funded by the company and run by a contract laboratory. That is a hypothesis-generating pilot. The underlying patent expired on 15 September 2023.
|
| Can you get your money back? |
OK
Yes - 90% of the net original purchase price less shipping, on product returned within one year of purchase and one year of cancellation, plus a 30-day money-back guarantee on retail product. This meets the mainstream direct-selling standard.
|
| Merchant play or miner play? |
WATCH
Mixed, and genuinely closer to merchant than most. Rank one can be reached with a real customer, advancement above it runs on organizational volume rather than headcount, and retail pays 25%. But Rapid Rewards, the Fast Start doubler, the Builder Bonus and the Leadership Pool all pay on enrollment events.
|
What has to be true for you to get paid
| To cover | You need |
|---|---|
| Join and hold Preferred Customer status | $25 waived on an opening order of 150 LP or more |
| Stay commission-eligible for a full year | ~$1,200–$1,440 100 LP a month at the catalog ratio of 340 LP for $399.95 |
| Cover that qualification from the median Associate commission | ~7–8x the median outcome against a published median of $15 a month - $180 a year - at the rank where 65.1% sit |
| Cover it from MyShop customer volume instead | ~$5,000–$5,800 of customer orders a year at the 25% commission on monthly customer volume above 100 LP |
Read this twice
Both sides of this sum come from the company’s own documents, which is why it is worth doing before anything else. The 2025 US income disclosure puts 65.1% of 23,185 disclosed affiliates at Associate rank, with an average of $42 a month and a median of $15 - $180 for the year. The plan requires 100 LP of personal volume every month to stay commission-eligible, and the company’s own US catalog prices a 340 LP Loyalty Pack at $399.95, which fixes the ratio at roughly 1 LP to $1.18 and puts the monthly qualification at $100–$120. So the typical disclosed participant is spending something like seven or eight times their annual commission simply to remain eligible to receive it, before the sales tools, events and travel the disclosure itself lists as costs it has not deducted. Three things cut the other way and belong in the same paragraph. The qualification can be met by MyShop customer orders rather than personal purchases, so an affiliate with a genuine customer base is not spending that money at all - the fourth line above is the version of this business that actually works. The company states that 88% of its customer accounts are purchase-only, used to buy product and not to enrol affiliates; if accurate that is a high customer-to-distributor ratio and the single best argument against a pyramid characterisation, though it is company-stated and unaudited. And the buyback is real: 90% of net original purchase price less shipping, within one year of purchase and one year of cancellation. The decisive caveat is scope. All of this arithmetic is United States arithmetic. For the markets the company’s own leadership calls the core of the business, no equivalent numbers have ever been published.
Run your own numbers
Drag the sliders. Nothing here is stored or sent.
Commission on a customer holding a monthly transfer-factor order, against the cost of the personal volume needed to stay commission-qualified - roughly $1,200 to $1,440 a year. That is why the cost slider starts high: you are buying product to keep the position before you sell any. The company publishes its own numbers and they are the calibration: the median monthly commission at the Associate rank, where 65.1% of US affiliates sit, is $15. The disclosure covers 23,185 US affiliates only, and the company operates in 25 markets. Your own subscription cost of $110/mo is included.
What it costs to replace this yourself
4Life’s own published US retail prices against open-market equivalents at the same ingredient class. Bovine colostrum is a commodity supplement sold by every mainstream retailer; the added mushroom blend and zinc in the flagship are inexpensive commodity ingredients on their own. The comparison is not a claim that the products are identical - it is the price-to-value question a buyer should be able to ask out loud, and the patent that once justified a premium expired on 15 September 2023.
| What they sell you | What you'd use instead | Your cost |
|---|---|---|
| Transfer Factor Plus Tri-Factor - $82.00, 30 servings ($2.73/day) | NOW Foods Colostrum 500 mg, 120 capsules at $33.99 ($0.28/capsule) | ~$8.50/mo |
| Transfer Factor Tri-Factor Formula - $49.00, 30 servings ($1.63/day) | Same mainstream colostrum, two capsules a day | ~$17/mo |
| The mushroom blend inside the Plus formula | Open-market reishi/maitake/shiitake blend capsules | ~$10–$20/mo |
| The zinc inside the Plus formula | Supermarket zinc, 100+ tablets | ~$1–$2/mo |
| 340 LP Loyalty Pack - $399.95–$414.95 | Buying only what you actually take, when you take it | $0–$40 |
| 100 LP monthly qualification - ~$1,200–$1,440/yr | No rank, no qualification, no automatic cancellation | $0 |
| $25 membership fee | No membership required to buy supplements anywhere | $0 |
| Regional events and annual convention travel | Not applicable | $0 |
| Total as sold ~$1,500–$1,800 in year one |
Total, built yourself ~$150–$300 of comparable supplementation |
Price-to-value
Roughly five to ten times the mainstream price on the flagship, and the gap widens rather than narrows once the structural costs are added. Two honest qualifications. First, brand and formulation premiums are normal in supplements and some buyers genuinely prefer a specific preparation - this is a real consumable with a real repeat-purchase base, not a novelty. Second, if a participant would happily pay $82 for this product at full price with no business attached, then the monthly qualification spend is consumption rather than cost, and the whole arithmetic changes. That distinction is the entire participant question here. The trouble is that the plan does not let you find out gently: the qualification is monthly, it is 100 LP whether you want the product that month or not, and six consecutive months without it cancels you.
Three operators, five horizons
Probability of cumulative net profit
Hover any point for median, top decile and bottom quartile.
Product-first affiliate
takes the product anyway, one or two customers, holds 100 LP a month
| Horizon | P(profit) | Median |
|---|---|---|
| 3 mo | 12% | −$310 |
| 6 mo | 14% | −$610 |
| 1 yr | 15% | −$1,180 |
| 3 yr | 16% | −$3,400 |
| 5 yr | 16% | −$5,600 |
Part-time builder
10 hrs/wk, MyShop customers plus some enrolling, Associate to Builder Elite
| Horizon | P(profit) | Median |
|---|---|---|
| 3 mo | 7% | −$520 |
| 6 mo | 10% | −$980 |
| 1 yr | 13% | −$1,700 |
| 3 yr | 17% | −$4,300 |
| 5 yr | 18% | −$6,600 |
Full-time builder
30+ hrs/wk, three legs, events and travel, chasing Diamond and above
| Horizon | P(profit) | Median |
|---|---|---|
| 3 mo | 3% | −$1,400 |
| 6 mo | 6% | −$2,700 |
| 1 yr | 10% | −$5,000 |
| 3 yr | 14% | −$12,000 |
| 5 yr | 16% | −$18,000 |
Methodology note. ANCHORED to 4Life’s own 2025 US income disclosure: 23,185 disclosed affiliates, 65.1% at Associate with an average of $42 a month and a median of $15; 4.4% at Builder and 16.2% at Builder Elite with medians of $59 and $155; 6.7% at Diamond and 3.7% at Diamond Elite with medians of $436 and $925; 2.4% at Presidential with a median of $2,344; and under 1% at every rank above that. Anchored also to the published median months to reach each rank - 15 months to Builder Elite, 38 to Diamond Elite, 55 to Bronze, 97 to Bronze Elite, 124 to Gold Elite and 220 to Platinum Elite - which is why the three-year and five-year rows show cohorts that are still climbing rather than arrived. Anchored to the published cost side: the $25 membership, the 100 LP monthly qualification at the catalog’s own 340 LP = $399.95 ratio, the 25% checkout discount, the 25% MyShop rate and the $399.95–$414.95 Loyalty Pack pricing. MODELED by us: the dollar expense side beyond those published items, because the disclosure names sales tools, travel and renewal fees as costs without giving a figure and does not publish the renewal amount at all; the share of each cohort in cumulative profit; and the three cohort definitions, which the company does not segment. Two calibration notes that cut in the company’s favor and matter. The 100 LP qualification can be satisfied by real MyShop customer orders rather than self-purchase, so an affiliate with an established customer base sits materially better than these medians - the medians describe the typical participant, and the typical participant does not have one. And for someone who would buy the product at full retail regardless, the qualification spend is consumption rather than business cost, which moves the product-first row close to flat. One further limit the reader should hold: every anchor above is United States data. These tables should not be read as describing an affiliate in Colombia, Mexico or the Dominican Republic, because nothing has ever been published about those markets.
Where you are actually allowed to promote this
Platform policy reads, not verifications. Check every one before you spend a dollar - enforcement changes faster than the written policy does.
Red flags and green flags
Red flags
151The only income disclosure covers one market out of twenty-five
2The scope of disclosure has narrowed since 2016
3The median affiliate at the modal rank earns $15 a month
4Qualification costs roughly $1,200–$1,440 a year against that $180
5The median holder of the top rank took 220 months to get there
6The flagship efficacy claim rests on a four-person trial
7123 documented distributor disease claims across eleven years
8An FDA warning letter to the founder personally, 1 November 2004
9A self-regulatory earnings-claims case closed only in December 2025
10Foreign distributors are the acknowledged compliance blind spot
11Price-to-value is poor and the patent moat has expired
12On exit you forfeit the organization entirely
13The renewal fee is open-ended and auto-deducted
14Complete financial opacity
15One federal case whose substance could not be established
Green flags
91No FTC action, consent order or warning letter - ever
2It publishes medians and time-to-rank, which is rarer than it should be
3Twenty-eight years of continuous trading since 1998
4Two documented, orderly CEO handovers
5Rank one can be reached with a customer, not only a recruit
6No investment contract anywhere in the structure
7Company-stated 88% purchase-only customer accounts
8A 90% buyback that meets the mainstream standard
9Documented, escalating compliance enforcement
We would like to be wrong about this
Upward
- Publish income disclosures for Colombia, Mexico, Peru, Ecuador, the Dominican Republic and Puerto Rico - or a single consolidated global disclosure with medians, as the company itself did worldwide in 2016 - and restore the global zero-earner figure it published then. This is the single largest available improvement and it is entirely within the company’s control.
- Fund and publish an adequately powered, independently conducted randomised controlled trial on the flagship immune claim, and drop the word "proven" until one exists; alongside that, publish audited group financials or at minimum a geographic revenue split, so the size of the undisclosed field stops being unknowable.
- Fix the annual renewal at a published amount rather than "as determined by the Company," publish the US Distributor Kit price, and commission a compliance audit covering non-US markets - the population the self-regulatory body itself identified as falling beyond direct control.
Downward
- Any FTC action, any new FDA warning letter, or any state attorney general action - particularly on immune or disease claims - or escalation of a self-regulatory case to the FTC rather than administrative closure.
- A confirmed adverse finding from INVIMA in Colombia, from the industry and commerce superintendency there, or from a health regulator in Mexico, Argentina or Peru; or evidence that the pending Utah federal case is a participant or consumer class action with adverse findings.
- Further narrowing of the income disclosure, or its replacement by a benefits document without medians; any increase in the 100 LP monthly qualification without a matching increase in payout; or a material fall in the company-stated 88% purchase-only customer share, which would change the whole customer-to-distributor analysis.
Grade is C-. A stable 28-year operator with a clean federal record and an unusually candid disclosure - that covers one market out of twenty-five, and shows the typical affiliate in it paying seven times more to qualify than they earn.
Take the good parts seriously first, because they are unusual. No FTC enforcement action, consent order or warning letter exists against this company at any date, and it is absent from both 2020 rounds of FTC warning letters to multi-level marketers over coronavirus claims - rounds that caught a long list of its peers. It has traded continuously since September 1998 with no insolvency, no receivership, no relaunch and no change of controlling family, through two documented and orderly CEO handovers. The founder’s prior venture, started in 1985, was a real operating business for more than a decade and is not attached to any enforcement action. The buyback is a genuine 90% within a year. The written income-claims policy is a total prohibition, including showing checks. And the income disclosure publishes medians alongside averages at all fifteen ranks, plus the median number of months taken to reach each one. Publishing that your median top-rank holder took 220 months to arrive is not something a marketing department volunteers.
Now the disclosure itself. Some 65.1% of the 23,185 disclosed US affiliates are at Associate, where the average is $42 a month and the median is $15 - $180 for the year. Staying commission-eligible requires 100 LP of personal volume every month, and the company’s own catalog prices a 340 LP pack at $399.95, which puts that qualification at roughly $100–$120 a month or $1,200–$1,440 a year. The typical disclosed participant is therefore paying seven or eight times their annual commission for the privilege of being eligible to receive it, before sales tools, events and travel, all of which the disclosure names as costs it has not deducted. There is a real escape hatch and it should be said clearly: the 100 LP can be met by MyShop customer orders instead of personal purchases, and an affiliate with a genuine customer base is not spending that money at all. That is the version of this business that works, and it is a sales job rather than a recruiting one.
The third element is what holds the grade at C-. That entire arithmetic is United States arithmetic. The company operates in twenty-five markets, its own vice-president of business intelligence describes thriving markets from Mexico to South America and a core segment of first- and second-generation Latinos on both US coasts, the trade profile records Spanish as the first operational language, and the 2026 event circuit ran Miami, Los Angeles, San Juan and Santo Domingo. No income disclosure exists for any of those Latin American markets. No country-level revenue split is published anywhere, so the relative size of the undisclosed field genuinely cannot be established in either direction - and that unprovability is itself the point. The 2016 disclosure was worldwide and said approximately 80% of all distributors received no income at all; the scope has narrowed since. Layer on a flagship claim of "clinically proven" resting on a four-participant company-funded trial, an expired patent, 123 cataloged distributor disease claims, and a Colombian policy in which the company forbids its own field from saying "Factor de Transferencia," and the shape is clear: a well-run, long-lived company whose published evidence stops exactly where its hardest questions begin.
Buy the product as a customer if you want it
The Preferred Customer route costs $25, waived on a 150 LP opening order, and carries no monthly qualification, no rank, no six-month cancellation clock and no forfeiture of anything. If the product is what you actually want, this is the honest version of the relationship. Then price it against a mainstream bovine colostrum at roughly $0.28 a capsule and decide whether the premium is one you want to pay every month.
Ask for the earnings data for your own market, in writing
If you are being recruited outside the United States, the only published disclosure does not describe you. Ask your sponsor and ask the company for the median monthly commission and the rank distribution for your country. If the answer is the US document, or a personal story, or a screenshot, you are being asked to make a financial decision on evidence that does not exist. Note the answer you get - it tells you a great deal about the organization you would be joining.
Do the $180-against-$1,320 sum before you sign anything
Both figures come from the company: a $15 median monthly commission at the rank where 65.1% sit, and a 100 LP monthly qualification priced by its own catalog at roughly $110 a month. If you cannot name a specific reason you will not be the median - a customer list you already have, a market you already sell into - then write down what you are actually buying, which is the product, and price it as product.
If you want to sell supplements, sell them without the qualification
The immune-support category is large and the search demand is real. Honest, sourced comparison content on colostrum peptides, on what a four-person feasibility trial can and cannot show, and on what structure/function claims are permitted under DSHEA, is a merchant business with genuine demand and no monthly buy-in. It requires no kit, no rank, no 100 LP a month, and nobody owns the organization you build except you.
Nine dimensions, weighted
Dimension profile
Further from center is better. Hover any point.
Hard caps that bind here
The lowest binding cap wins, regardless of the weighted arithmetic.
What we read
Every source below links to the document itself. Tier 1 is a primary record - the company’s own plan, policy or disclosure, a court filing, a regulator’s decision or an SEC filing. Tier 2 is a self-regulatory or secondary regulator record, tier 3 reporting or academic work, tier 4 an open-market price comparison. Where a document can be moved or withdrawn, an archived copy is linked beside it. If a link is dead when you try it, that is a correction we want.
- 4Life "Preferred Customer and Affiliate Benefits" Income Disclosure Statement, 1 January – 31 December 2025 (US edition on 4life.com) - 23,185 affiliates; $25 Preferred Customer enrollment fee; $15 annual affiliate fee; the 88% purchase-only customer statement; the expenses-may-exceed-earnings warning
4Life "Preferred Customer and Affiliate Benefits" income disclosure covering 1 January to 31 December 2025, published at media2.4life.com and on the company policies page - 23,185 US affiliates; Associate 65.1% at an average $42 and median $15 a month with a median 3 months to achieve; Builder 4.4%, Builder Elite 16.2% (median $155), Diamond 6.7% (median $436), Diamond Elite 3.7% (median $925, 38 months), Presidential 2.4% (median $2,344); Bronze Elite 97 months, Gold Elite 124 months, Platinum Elite median $287,156 a month and 220 months to achieve; the 88% purchase-only customer statement; and the statement that these amounts do not consider expenses including renewal fees, sales tools and travel, which may exceed the amount earned
Not established by this document: media2.4life.com does not serve a standalone PDF of the 2025 disclosure at any path reachable from search; the disclosure is rendered from the policies page above. The US page is robots-disallowed to the standard fetcher but retrievable through the alternate fetcher, and the rank-by-rank table renders identically on the market mirror cited second.
- 4Life Research (2025) Direct Seller earnings by rank, distribution and time to achieve - the same 2025 rank table as served on a 4life.com market site (Associate 65.1%; Builder Elite 16.2% / $155 median; Diamond Elite 3.7% / $925; Gold Elite 124 months; Platinum Elite $287,156 median and 220 months)
- 4Life Income Disclosure Statement 2016 (worldwide scope) - "approximately 80% of all distributors received no income at all" during 2016 (reproduced in an advocacy organization's income-disclosure compilation, PDF)
4Life 2016 Income Disclosure Statement, worldwide scope, reproduced by an advertising advocacy organization - "approximately 80% of all distributors received no income at all" during 2016; the comparison that establishes the narrowing of disclosure scope
- 4Life Compensation Plan - official US plan page, 4life.com (Life Points; MyShop 25%; Rapid Rewards 25%/12%/5%; Me and My 3 Builder Bonus at $50/$200/$800; rank qualifications; Infinity Payout from Diamond; Leadership Pool, Premier Pool at 2% of company LP and Platinum Pool at 1%)
4Life Compensation Plan 2026 (English) and the October 2020 US Life Rewards Plan brochure - the fifteen-rank ladder from Associate to Platinum Elite, 100 PV monthly at every rank, 1,000 to 2,000,000 LP monthly organizational volume, first-level 25% and second-level 2% at Associate and Builder, generation percentages to ten generations, the infinity dynamic beginning at Diamond, monthly compression of non-qualifiers, Rapid Rewards at 25%/12%/5%, the $50/$200/$800 Builder Bonus and its $100/$400/$1,600 doubler, $200–$20,000 rank bonuses, the Leadership, Premier (2% of company LP) and Platinum (1%) pools, and the company-stated $3 billion in cumulative commissions paid
Not established by this document: The October 2020 US-edition Life Rewards Plan brochure is no longer served at any 4life.com path found in search; 4Life replaces the brochure in place at /corp/Policies/Life_Rewards_Brochure per market. The 2026 booklet cited is the currently served edition and is the same document family; the US-specific dollar figures ($50/$200/$800 Builder Bonus, $200–$20,000 rank bonuses) appear on the US comp-plan page cited first.
- 4Life Compensation Plan brochure, effective 1 January 2026 (full plan booklet as published on a 4life.com market site) - fifteen-rank ladder, 100 PV monthly, monthly compression of non-qualifiers, Infinity Payout and Infinity Pass Through mechanics, Fast Start and Double Builder Bonus tables
- 4Life Transfer Factor Plus Tri-Factor Formula product page, 4life.com - $82.00 for 60 capsules, and the verbatim claim "A daily dose (600 mg) of 4Life Transfer Factor is clinically proven to activate the immune system within two hours"
4Life US Product Catalog and product pages, 2026 - Transfer Factor Loyalty Pack item #53433 at $399.95 for 340 LP, which fixes the LP-to-dollar ratio at roughly 1 LP to $1.18; Transfer Factor Plus Tri-Factor at $82.00 for 60 capsules; Transfer Factor Tri-Factor Formula at $49.00; the "clinically proven to activate the immune system within two hours" claim and the DSHEA disclaimer. Comparator: NOW Foods Colostrum 500 mg, 120 capsules, $33.99
Not established by this document: The 2026 US Product Catalog PDF and the Transfer Factor Loyalty Pack item #53433 listing at $399.95 / 340 LP sit behind the authenticated 4Life shop and did not surface in search; the LP-to-dollar ratio therefore cannot be linked to a public page. The NOW Foods Colostrum 500 mg comparator price was not separately sourced.
- 4Life Transfer Factor Core Products page, 4life.com - Transfer Factor Tri-Factor Formula $62.00, Transfer Factor Plus $82.00, RiteStart Men/Women $99.00
- 4Life Transfer Factor Plus Tri-Factor Formula US Product Profile Sheet (PDF on media2.4life.com) - item number, supplement facts and the DSHEA disclaimer
- 4Life Policies and Procedures (4Life Research Europe edition, full bilingual text, PDF) - §2.4 subscription fee "as determined by the Company" deducted from bonus earnings; §3.14 product and disease claims; §3.15 income claims; §3.18 conflicts of interest / non-recruitment
4Life Policies and Procedures (4Life Research Europe edition, the accessible full text; the current US edition returns a 403) - §2.5 renewal "as determined by the Company" deducted from bonus checks, §3.2 prior approval of all sales aids and websites, §3.13 product and disease-claim prohibition, §3.14 total income-claim prohibition including showing checks, §3.17 twelve-month non-solicitation, §7.3 90% buyback within one year, §10.1 forfeiture of the downline organization on cancellation, §10.2 automatic cancellation after six months of inactivity
Not established by this document: The current US edition of the 4Life Policies and Procedures returns 403 to every retrieval path tried; the Europe edition is the accessible full text and its section numbering is the one the prose cites.
- Yu L, Iloba I, Cruickshank D, Jensen GS, "Feasibility Trial Exploring Immune-Related Biomarkers … after Consuming a Nutraceutical Supplement Containing Colostrum- and Egg-Based Low-Molecular-Weight Peptides," Curr Issues Mol Biol 2024;46(7):6710–6724 (PMC11275817)
Yu L, Iloba I, Cruickshank D, Jensen GS, "Feasibility Trial Exploring Immune-Related Biomarkers … after Consuming a Nutraceutical Supplement Containing Colostrum- and Egg-Based Low-Molecular-Weight Peptides," Current Issues in Molecular Biology 2024;46(7):6710–6724 (PMC11275817) - double-blind randomised placebo-controlled cross-over pilot in four healthy participants, blood draws at baseline, 1 h, 2 h and 24 h, funding statement declaring 4Life as funder, all four authors affiliated with a contract research laboratory. Google Patents US6866868B1, filed 15 September 2003, granted 15 March 2005, expired 15 September 2023
Not established by this document: A Google Patents URL for US6866868B1 was not returned verbatim by any search performed, so no link is emitted for the patent. 4Life's own product pages confirm the patent number ("U.S. patents 6,468,534 and 6,866,868") - see https://singapore.4life.com/corp/product/details/89 - but the register entry itself was not retrieved.
- Publisher's record of the same paper, including the funding statement and author affiliations - Curr. Issues Mol. Biol. 2024, 46(7), 6710-6724, doi:10.3390/cimb46070400
- FDA Warning Letter to David Lisonbee, 4Life Research, Sandy, Utah, 1 November 2004, Ref. No. CL-04-HFS-810-108 - naming 4Life Transfer Factor GluCoach, BioGenistein Plus and Transfer Factor ReCall as unapproved new drugs under FDCA §§201(g)(1) and 201(p)
FDA enforcement letter database and the Quackwatch index - warning letter to David Lisonbee, 4Life Research, Sandy, Utah, 1 November 2004, reference CL-04-HFS-810-108, naming Transfer Factor GluCoach, BioGenistein Plus and Transfer Factor ReCall; letter body behind a subscription wall. FTC press releases of April 2020 and June 2020 listing recipients of MLM coronavirus warning letters - 4Life appears in neither, and no FTC action or consent order against the company was located at any date
Not established by this document: The FDA's own enforcement database entry for CL-04-HFS-810-108 is not retrievable (letters of that vintage sit behind fda.gov's retired warning-letter archive and a subscription wall), so the letter body is cited from the two republished copies above. The FTC's April 2020 and June 2020 MLM coronavirus warning-letter press releases were not separately retrieved in this session; the negative finding stated in the prose - that 4Life appears on neither list - is therefore unlinked.
- FDA Warning Letter to 4Life Research, 1 November 2004 - scanned copy of the letter as issued (PDF)
- Quackwatch index - FDA Warning Letters about Products (2004), listing "4Life Research / David Lisonbee (11/1/04)"
- California Attorney General Proposition 65 60-Day Notice 2010-00254, filed 29 June 2010 against 4Life Research, LLC - Notice of Violation naming 4Life Transfer Factor Cardio, MusculoSkeletal and E-XF (PDF)
California Attorney General Proposition 65 record, 60-day notice 2010-00254 filed 29 June 2010 alleging lead in herbal dietary supplements, settled by consent judgment 8 June 2012 - $75,000 total comprising a $6,448 civil penalty, $49,210 in attorney fees and costs and $19,342 in lieu of additional penalties, with a 0.5 µg maximum-daily-dose lead limit or warning requirement; private-enforcer action, no admission of liability
Not established by this document: The 8 June 2012 consent judgment itself - the $75,000 total, the $6,448 civil penalty / $49,210 fees / $19,342 in-lieu split and the 0.5 µg maximum-daily-dose lead limit - is filed in the Prop 65 settlements register rather than the 60-day notice register and did not resolve to a retrievable oag.ca.gov URL.
- BBB National Programs, Direct Selling Self-Regulatory Council Case #244-2026: Administrative Closure - 4Life Research, LLC, closed 22 December 2025 (nine social posts; three removed, one modified, a website testimonial revised; three Philippines-based and one Colorado poster)
BBB National Programs, Direct Selling Self-Regulatory Council Case #244-2026, administrative closure 22 December 2025 - nine social-media posts from May 2023 to September 2025 including "half a million month after month," three from Philippines-based distributors and one from Colorado; company removed three posts, modified one, revised a website testimonial, suspended non-responsive accounts and engaged third-party monitoring. Advocacy-organization databases: 123 documented distributor health claims 2005–2016 and an income-claims database spanning 2018–2023
- DSSRC Case #244-2026 administrative closure (PDF copy)
- TINA.org 2017 4Life Income Claims Database - the advocacy-organization income-claims record for the company
- TINA.org letter to 4Life Research CEO Steve Tew, 6 June 2016 - the health-claims investigation behind the 123 documented distributor disease claims (PDF)
- Direct Selling News company profile, "4Life: A Legacy of Wellness, Service and Global Community" (28 January 2025) - 1998 founding, Utah base, Latin America as core focus, Spanish as the company's first operational language, "our largest segment is the first- and second-generation Latino market in the United States"
Direct Selling News company profile of 28 January 2025 and the DSN Global 100 historical listing - 1998 founding, Utah base, $150 m in 2009 and $200 m in 2010, Latin America as "core focus," Spanish as first operational language, "our largest segment is the first- and second-generation Latino market in the United States"; BBB business profile (start date 3 September 1998, A+ rating, accredited since 3 February 2014 - a private ratings body’s purchased accreditation, not a regulatory endorsement); DSA member record (twenty-five countries, NSF-registered manufacturing); GlobeNewswire, 31 October 2017, "4Life Research Names New CEO"; and 4Life Colombia’s published twenty-five-word prohibited-claims list requiring INVIMA pre-approval
Not established by this document: Not separately retrieved in this session: the BBB business profile for 4Life Research (start date 3 September 1998, accredited 3 February 2014), the DSA member record for twenty-five countries and NSF-registered manufacturing, the GlobeNewswire release of 31 October 2017 "4Life Research Names New CEO", and 4Life Colombia's published twenty-five-word prohibited-claims list requiring INVIMA pre-approval. The 2017 CEO appointment is corroborated by the company page cited above.
- Direct Selling News, "The New LATAM Strategy" (1 January 2025) - 4Life VP of Business Intelligence: "Our business is supported 90 percent by LATAM"
- 4Life corporate "Company" page - BBB A+ rating claim, Direct Selling News Global 100 appearances, and the 2017 appointment of Danny Lee as President and CEO
What we could not get
- Any earnings data whatsoever for markets outside the United States. None exists in the public domain - not for Colombia, Mexico, Peru, Ecuador, the Dominican Republic, Puerto Rico as a separate market, or anywhere else. This is the largest single gap in the file and it is the reason the disclosure finding is written as scope rather than as a claim about outcomes.
- Any country-level revenue split for the group. The frequently repeated premise that Colombia alone accounts for around half of company volume could not be confirmed from any company, regulatory or trade source and is not asserted here. What is verifiable is the executives’ own "Latin America is the core" statements, the twenty-five-market footprint against 23,185 disclosed US affiliates, and that the Colombian subsidiary employed 59 people in 2026 with 2025 net sales up 10.93% and net profit up 30.55% - percentages only, since the absolute peso figures are paywalled.
- The cause of action and disposition of Hazel v. 4Life Research LLC, District of Utah, 2:24-cv-00487. The docket is paywalled, so whether it carries class allegations, what it alleges and how it ended are all unknown. Nothing is asserted about it.
- The exact claims and FDCA sections cited in the 1 November 2004 FDA warning letter - the letter body sits behind a subscription wall and robots restrictions, so only the date, addressee, reference number and the three named products are established.
- The substance of the two INVIMA sanitary alerts issued in Colombia in 2023 naming a 4Life transfer-factor product and a 4Life digestive-enzyme product. The alerts exist and are circulated through departmental pharmacovigilance channels, but the texts could not be retrieved, so whether the grounds were counterfeit product, product without sanitary registration, or a claims issue is not established. These are health-authority alerts, not sanctions and not findings against the company.
- The current US Distributor Kit price and the current annual renewal amount. The policies state only that the renewal is a material and subscription fee "as determined by the Company," and no figure is published in any accessible document. Event and convention ticket pricing and expected travel spend are likewise unpublished.
- The current US Policies and Procedures wording - the live US page returns a 403, so the section quotations above are taken from the 4Life Research Europe edition and may differ from the current US text. Similarly, the exact level-by-level commission percentages in the 2026 US plan edition extracted inconsistently against the 2020 US and India editions; the plan shape given here is the reliable statement.
- Whether the 23,185 figure includes affiliates who received no commission at all - the disclosure says it covers affiliates who received a commission payment during 2025, which reads as excluding zero-earners, but the wording is ambiguous and the company does not clarify it. Also unverified: the corporate fate of the founder’s prior venture after 2000, audited group revenue, and exhaustive clearance from the Colombian industry and commerce superintendency or from health regulators in Mexico, Argentina, Peru and Spain - targeted searches returned nothing adverse, but those archives are not fully open-indexed.
Not advice
This is independent analysis for decision-making, not legal, financial or investment advice. Allegations reported by third parties should be verified against primary court and regulatory records before any decision.
Researched by Claude. Reviewed by an editor.
Every report is researched and written by Claude, Anthropic’s AI assistant, from the company’s own plan documents, policies, terms and regulatory file - then reviewed before publication by Rob Fore, who checks the sources and the stage-label on every allegation.
- Nine weighted dimensions, published with their weights
- The editor checks the evidence and cannot change the number - the build rejects any page whose grade does not reconcile to its own arithmetic
- Every affiliate position we hold is disclosed on the report it touches
- No company has paid for a grade, and no report carries an affiliate link
Looking at something else?
Enter any company name or website. If a report exists it opens instantly; if not, we start one.
4Life - frequently asked
QIs 4Life Research a pyramid scheme?
QHow much do 4Life affiliates actually earn?
QWhy does the income disclosure only cover the United States?
QIs transfer factor clinically proven to work?
QWhat does it cost to join 4Life and what happens if you stop buying?
Author, editor and publisher
This report was researched and written by Claude, Anthropic’s AI assistant, working from primary documents - 4Life’s own compensation plan, its policies and procedures, its terms of service, its income disclosure statement where one exists, and its regulatory and self-regulatory file. It was scored against nine weighted dimensions that are published in full, with their weights, on the methodology page.
Before publication it was reviewed by Rob Fore, who checks every source link, every figure against the document it came from, and every allegation against its stage-label - an investigation is not a finding, a warning letter is not an enforcement action, and a filed claim is not a verdict.
The editor does not set the grade. The published score is the weighted composite of the nine dimension scores, and the build refuses to emit a page where the two disagree by more than 0.06. A grade moves when the evidence moves it and not otherwise.
Rob Fore has marketed online since 1996, wrote Online MLM Marketing (2014), and is CEO of Listech Inc, the Nevada corporation that publishes this site. He holds affiliate positions in companies graded here - including LiveGood, which this site grades D, SendOutCards, which it grades C−, and the Home Business Academy, which it grades B−. Those positions are disclosed on the reports they touch, and changed nothing on this page.
About the author and our conflicts · Contact the editor · Corrections: corrections@opportunitygrade.com
Tell me if this grade changes
4Life is graded C- as of July 29, 2026. Grades move when the evidence moves - a new income disclosure, a regulatory action, a rewritten compensation plan. Leave your address and you will get one email if this one does.
One email when the grade moves, and nothing else. We will never use your address to promote an income opportunity of any kind, we do not sell, rent or share the list, and it is stored on our own infrastructure rather than with any company graded here. Unsubscribe removes everything.
Corrections
Every factual claim on this page is sourced, and the ones we could not stand up are named in the unable to verify list above. If something here is wrong, we want to know, and we would rather hear it from 4Life than from a reader.
Write to corrections@opportunitygrade.com. Point at the specific sentence and send the document that contradicts it - a plan document, a filing, an income disclosure, a policy page. We will check it against the primary source, correct the page if it is wrong, and say in the report that it was corrected and when. A grade moves if the evidence moves it.
This address reaches a person, not a form. We do not require a takedown demand, an NDA or a lawyer to accept a correction, and we do not remove a report because a company disputes its conclusion - only because the underlying facts turn out to be wrong.